HK1104062A1 - Modulation of wrn-mediated telomere-initiated cell signaling - Google Patents

Modulation of wrn-mediated telomere-initiated cell signaling

Info

Publication number
HK1104062A1
HK1104062A1 HK07112486.9A HK07112486A HK1104062A1 HK 1104062 A1 HK1104062 A1 HK 1104062A1 HK 07112486 A HK07112486 A HK 07112486A HK 1104062 A1 HK1104062 A1 HK 1104062A1
Authority
HK
Hong Kong
Prior art keywords
wrn
modulation
cell signaling
initiated cell
mediated telomere
Prior art date
Application number
HK07112486.9A
Other languages
English (en)
Inventor
A Gilchrest A Barbara
S Eller S Mark
Original Assignee
Univ Boston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Boston filed Critical Univ Boston
Publication of HK1104062A1 publication Critical patent/HK1104062A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
HK07112486.9A 2004-05-19 2007-11-15 Modulation of wrn-mediated telomere-initiated cell signaling HK1104062A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57262504P 2004-05-19 2004-05-19
PCT/US2005/017553 WO2005113764A2 (en) 2004-05-19 2005-05-19 Modulation of wrn-mediated telomere-initiated cell signaling

Publications (1)

Publication Number Publication Date
HK1104062A1 true HK1104062A1 (en) 2008-01-04

Family

ID=34982215

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07112486.9A HK1104062A1 (en) 2004-05-19 2007-11-15 Modulation of wrn-mediated telomere-initiated cell signaling

Country Status (16)

Country Link
US (1) US20080221052A1 (de)
EP (2) EP2434009A1 (de)
JP (1) JP2007537758A (de)
KR (1) KR20070030219A (de)
CN (2) CN101869575A (de)
AU (1) AU2005245932A1 (de)
BR (1) BRPI0511142A (de)
CA (1) CA2566859C (de)
HK (1) HK1104062A1 (de)
IL (1) IL179199A (de)
MX (1) MXPA06013263A (de)
NO (1) NO20065782L (de)
NZ (1) NZ551323A (de)
RU (1) RU2006144817A (de)
TR (2) TR200606490A2 (de)
WO (1) WO2005113764A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100086941A1 (en) * 2008-10-01 2010-04-08 Adami Guy R Methods for determining aged based accumulation of senescent cells using senescence specific DNA damage markers
US20110052676A1 (en) * 2009-09-01 2011-03-03 James Vincent Gruber Composition For Delaying Cellular Senescence
RU2550267C2 (ru) * 2012-12-12 2015-05-10 Елена Андреевна Чирясова Способ воздействия на пролиферативный статус клеток с помощью специфических нуклеотидных последовательностей g-цепи теломерной днк человека
US11530413B2 (en) 2017-07-21 2022-12-20 Novartis Ag Compositions and methods to treat cancer
US20210371855A1 (en) * 2018-06-15 2021-12-02 Ideaya Biosciences, Inc. Methods of inhibiting proliferative cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2534487B1 (fr) * 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
US5077211A (en) * 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
WO2001074342A2 (en) * 2000-03-31 2001-10-11 Trustees Of Boston University Use of locally applied dna fragments
US6090620A (en) * 1995-12-29 2000-07-18 University Of Washington Genes and gene products related to Werner's syndrome
US6228583B1 (en) * 1997-08-04 2001-05-08 Massachusetts Institute Of Technology Assays for compounds which extend life span
SE0200929D0 (sv) 2002-03-26 2002-03-26 Alstom Switzerland Ltd An apparatus and method for suspending a stator core of an electric generator
AU2004233188A1 (en) 2003-04-11 2004-11-04 Trustees Of Boston University Modulation of telomere-initiated cell signaling

Also Published As

Publication number Publication date
WO2005113764A3 (en) 2006-03-30
CN1965076A (zh) 2007-05-16
TR200606490A2 (tr) 2008-05-21
KR20070030219A (ko) 2007-03-15
EP2434009A1 (de) 2012-03-28
US20080221052A1 (en) 2008-09-11
AU2005245932A1 (en) 2005-12-01
BRPI0511142A (pt) 2007-12-04
RU2006144817A (ru) 2008-06-27
CA2566859A1 (en) 2005-12-01
NZ551323A (en) 2010-03-26
CN1965076B (zh) 2011-01-26
EP1761629A2 (de) 2007-03-14
MXPA06013263A (es) 2007-08-14
JP2007537758A (ja) 2007-12-27
NO20065782L (no) 2006-12-18
WO2005113764A2 (en) 2005-12-01
IL179199A0 (en) 2007-03-08
CA2566859C (en) 2011-07-19
TR200606490T1 (tr) 2007-01-22
IL179199A (en) 2010-12-30
CN101869575A (zh) 2010-10-27

Similar Documents

Publication Publication Date Title
EP1797691A4 (de) Blockmodulation
IL178564A0 (en) Improved modulators of coagulation factors
EP1718308A4 (de) Verfahren zur modulierung der neurotrophin-vermittelten aktivität
PL382382A1 (pl) Przebijalne uszczelnienie
EP1841001A4 (de) Bipolar-batterie
EP1799866A4 (de) Modulierende mxa-expression
ZAA200500371S (en) Battery
GB0410118D0 (en) Novel bioreactor
EP2040730A4 (de) Modulation von nkg2d
EP1751115A4 (de) Theramuteinmodulatoren
PL1704287T3 (pl) Folia kubełkowa
EP1799739A4 (de) Gele
ZA200703293B (en) Cell bandage
HK1104062A1 (en) Modulation of wrn-mediated telomere-initiated cell signaling
EP1909820A4 (de) Modulation der granulosa-zell-apoptose
HK1081578A1 (en) Electrophoretic nano-coating
GB0420881D0 (en) Bioreactor
EP1889061A4 (de) Modulation der t-zell-rekrutierung
EP1819722A4 (de) Modulation der ovulation
GB0400289D0 (en) Electro-optical cell
GB2418056B (en) Battery
ZA200702966B (en) Cryopreservation of cells
EP1946573A4 (de) Signalisierung von zellenkombinierfähigkeiten
GB0401475D0 (en) Method of signalling
GB0526515D0 (en) Modulation of signalling pathways

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150519